has been a large resistance level that is just itching to be broken. Raj could sign a marketing deal for 2012 in Europe which would create a large cash infusion and send the non hedged shorts scrambling. Sooner or later there has to be an EU marketing deal even if Raj plans on going it alone in the USA. The CE-Melphalan drug approval will negate much of the past dependence on Fusilev income. A court ruling against Novartis' generic dosing for colorectal cancer would be another source of ignition to a short squeeze.
they have not procured a BP marketing partner for years now and they are on the hook big time to run the cardiovascular safety trials which will be costly. The company has huge financial liabilities and that is why the PPS keeps dwindling. The converts will probably be eventually turned into stock and that is how the short position will cover at rock bottom. The very hedge funds short will help keep Vivus fot.